The effect of N-acetylcysteine in GAD

Comparison of the effect of N-acetylcysteine ??and standard treatment on anxiety score in patients with generalized anxiety disorder

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150706023083N5

Enrollment

100

Registered

2020-08-09

Start date

2020-07-05

Completion date

Unknown

Last updated

2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized anxiety disorder. Generalized anxiety disorder

Interventions

Intervention 1: Intervention group: Including 50 patients who, in addition to receiving standard treatment for anxiety disorder, receive N-acetylcysteine ??for 2 months at a daily dose of 600 mg . Int

Eligibility

Sex/Gender

All

Age

17 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with GAD disorder at the discretion of a psychiatrist based on DSM-V criteria and Spit-zer questionnaire

Exclusion criteria

Exclusion criteria: Patients with hepatic encephalopathy , asthma, gastric hemorrhage and fluid overload Taking anticonvulsant drugs Other Mental disorders such as autism, seizures and chronic diseases Pregnant and lactating women Inability to understand and sign consent

Design outcomes

Primary

Measure	Time frame
Anxiety score. Timepoint: On arrival and after 2, 4, 6, 8 weeks after receiving medicine. Method of measurement: Spit-Zer Anxiety Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Haleh Rezaee

Tabriz University of Medical Sciences

Rezaeeha@tbzmed.ac.ir+98 41 3337 2250

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026